{
    "title": "Mirati to focus adagrasib/Keytruda study in low PDL1 lung cancer patients",
    "url": "https://www.dailymail.co.uk/wires/reuters/article-11505669/Mirati-focus-adagrasib-Keytruda-study-low-PDL1-lung-cancer-patients.html",
    "date": "2022-12-05",
    "keywords": [
        "combination",
        "drug",
        "trial",
        "adagrasib",
        "year",
        "treatment",
        "mirati",
        "beasley",
        "keytruda",
        "lung",
        "side",
        "pdl1",
        "phase",
        "study",
        "chemotherapy",
        "form",
        "tumor",
        "approval",
        "dec",
        "merck",
        "amp",
        "cos",
        "immunotherapy",
        "half",
        "cancer",
        "monday",
        "company",
        "advantage",
        "protein",
        "end",
        "officer",
        "david",
        "meek",
        "standard",
        "care",
        "pembrolizumab",
        "nsclc",
        "placebo",
        "gene",
        "nonsmall",
        "cell",
        "disease",
        "followup",
        "shrinkage",
        "none",
        "growth",
        "analysis",
        "liver",
        "amgen",
        "inc",
        "krasinhibitor",
        "toxicity",
        "application",
        "food",
        "administration",
        "takeover",
        "speculation",
        "midnovember",
        "line",
        "reporting",
        "deena",
        "matthew",
        "lewis"
    ],
    "category": [
        "wires",
        "reuters"
    ]
}